Page last updated: 2024-08-21

quinazolines and Cancer of Head

quinazolines has been researched along with Cancer of Head in 290 studies

Research

Studies (290)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (0.69)	18.7374
1990's	9 (3.10)	18.2507
2000's	125 (43.10)	29.6817
2010's	150 (51.72)	24.3611
2020's	4 (1.38)	2.80

Authors

Authors	Studies
Ahn, BC; Cho, BC; Heo, SG; Hong, MH; Kim, HR; Lee, JH; Lim, SM	1
Lang, L; Teng, Y	1
Clement, PM; Cohen, EEW; Cupissol, D; de Souza Viana, L; Fayette, J; Gauler, T; Geng, Y; Geoffrois, L; Guigay, J; Haddad, R; Keilholz, U; Kornek, G; Licitra, L; Machiels, JP; Melichar, B; Rauch, D; Ribaldo Nicolau, U; Rolland, F; Tahara, M; Vermorken, J; Zanetta-Devauges, S; Zografos, E	1
Lang, L; Shay, C; Teng, Y; Wang, X; Xiong, Y; Zhao, X	1
Amendt, C; Blaukat, A; Dahmen, H; Fuchss, T; Grombacher, T; Kirkin, V; Pehl, U; Sirrenberg, C; Vassilev, LT; Wilm, C; Zenke, FT; Zimmermann, A	1
Akashi, M; Fukuoka, T; Hasegawa, T; Kakei, Y; Kashin, M; Sasaki, R; Teraoka, S; Yamaguchi, A	1
Batra, SK; Ganti, AK; Gupta, S; Jahan, R; Jain, M; Jones, DT; Kibe, T; Kishida, M; Kishida, S; Li, S; Lin, C; Lydiatt, WM; Macha, MA; Nakamura, N; Patel, A; Qazi, AK; Rachagani, S; Seshacharyulu, P; Smith, RB; Verma, V; Wang, S	1
Aderhold, C; Birk, R; Hock, C; Hörmann, K; Kramer, B; Kuhlin, B; Lammert, A; Schultz, JD	1
Bertrand, D; Chia, S; Chong, FT; DasGupta, R; Gopalakrishna Iyer, N; Hentze, H; Hui Choo, S; Hwang, JSG; Koh, JLY; Kwang, XL; Leong, HS; Lezhava, A; Lim, KH; Low, JL; Periyasamy, G; Sharma, A; Skanthakumar, T; Su, Y; Tan, DSW; Tan, HK; Tan, IBH; Tan, P; Thangavelu, MT; Toh, SY; Zhang, X	1
Ang, MK; Chang, MM; Chong, FT; Chowbay, B; Chua, BT; DasGupta, R; Iyer, NG; Kwang, XL; Lau, DP; Leong, HS; Lim, TKH; Lim, WT; Sampath, P; Skanderup, AJ; Sundaram, GM; Tan, DSW; Tan, EH; Tan, GS; Toh, SY; Zhang, X	1
Burtness, B; Clement, PM; Cohen, EEW; Cong, XJ; Del Campo, JM; Dupuis, N; Ehrnrooth, E; Fayette, J; Gauler, T; Geoffrois, L; Gibson, N; Grau, JJ; Guigay, J; Haddad, RI; Krämer, N; Licitra, LF; Machiels, JH; Mailliez, A; Merlano, MC; Solca, F; Tahara, M; Vermorken, JB	1
Nanbu, K; Nanbu, T; Ohkoshi, E; Sakagami, H; Shimada, J; Umemura, N	1
Chemmalakuzhy, R; Lang, L; Shay, C; Teng, Y; Thakkar, P; Wang, X; Xiong, Y	1
Brenner, JC; Carey, TE; Harris, M; Herbst, G; Jiang, H; Kulkarni, A; Leonard, E; Matovina, C; Michmerhuizen, NL; Zhai, J	1
Brands, RC; El-Mesery, M; Hartmann, S; Kübler, AC; Müller-Richter, UDA; Scheurer, MJJ; Seher, A	1
Chu, PL; Chua, KLM; Chua, MLK; Liang, ZG; Low, KP; Nei, WL; Poon, DJJ; Ramaswamy, B; Shihabuddeen, WA; Soo, KC; Thong, PSP; Yeo, ELL	1
Ather, F; Fejzo, MS; Finn, RS; Hamidi, H; Head, C; Kabbinavar, F; Letrent, S; Wong, SG	1
Amin, AR; Beitler, JJ; Brandes, JC; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, WJ; Khuri, FR; Kono, S; Lewis, M; Moreno-Williams, R; Müller, S; Nannapaneni, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Thomas, SM; Zhang, H	1
Braakhuis, BJ; Brakenhoff, RH; Martens-de Kemp, SR; Nagel, R; Stigter-van Walsum, M; van Beusechem, VW; van der Meulen, IH	1
Austin, M; Bauman, JE; Chai, X; Eaton, KD; Futran, N; Hayes, DN; Kurland, BF; Liao, JJ; Martins, RG; Mendez, E; Papagikos, MA; Parvathaneni, U; Raez, LE; Schmidt, R; Sharma, AK; Wallace, SG; Wang, DX; Yunus, F	1
Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K	1
Bontognali, S; Brutsche, MH; Buess, M; Fischer, C; Pless, M; Rochlitz, C	1
Al-Lazikani, B; Box, C; Box, GM; Brandon, Ade H; Eccles, SA; Gowan, S; Harrington, KJ; Mendiola, M; Rogers, SJ; Valenti, M; Wilkins, A	1
Bhatt, VR; Ganti, AK	1
Bhave, S; Bruno, PA; Datta, J; Lang, JC; Mapp, AK; Pan, Q; Piao, L; Su, T; Taylor, CE; Teknos, TN; Xie, X; Zhang, M	1
Adkins, D; Clark, J; Haddad, R; Jaffa, Z; Limaye, S; O'Neill, A; Posner, M; Riley, S; Zhao, S	1
He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y	1
Chalasani, P; Clausen, C; Dhiwakar, M; Kalapurakal, S; Malone, J; Rao, K; Robbins, KT; Robinson, K; Ronen, O; Shevlin, B	1
Case, AJ; Domann, FE; Fletcher, EV; Love-Homan, L; Miller, FJ; Raeburn, A; Schickling, BM; Simons, AL; Sobhakumari, A	1
Chen, ZG; Curran, WJ; Deng, X; Hu, Z; Khuri, FR; Li, R; Shin, DM; Sica, GL; You, S	1
Candy, PA; Epis, MR; Giles, KM; Goodall, GJ; Kalinowski, FC; Leedman, PJ; Redfern, AD; Stuart, LM; Zhang, PM	1
Feddersen, CR; Fletcher, EV; Goel, A; Koch, AT; Love-Homan, L; Simons, AL; Sobhakumari, A	1
Austin, MC; Bauman, JE; Chai, X; Hayes, DN; Kurland, BF; Martins, RG; Mendez, E; Parvathaneni, U; Sampath, S; Schmidt, R; Vaezi, A	1
Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, W; Hurwitz, SJ; Khuri, FR; Kono, SA; Lewis, M; Moore, CE; Moreno-Williams, R; Müller, S; Nannapaneni, S; Owonikoko, TK; Ramalingam, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Yang, CS; Zhao, Y	1
Andrews, GA; Byers, LA; Fooshee, DR; Frederick, MJ; Galer, C; Hah, JH; Heymach, J; Jasser, SA; Kim, E; Milas, ZL; Myers, JN; Papadimitrakopoulou, V; Pickering, CR; Sano, D; William, WN; Zhao, M	1
Ferrarotto, R; Gold, KA	1
Gauler, TC; Harbeck, N; Solca, F	1
Eicheler, W; Holler, M; Meier, F; Minjgee, M; Rodemann, HP; Saki, M; Toulany, M	1
Akar, A; Altiok, S; Bepler, G; Chiappori, A; Gray, JE; Haura, E; Kish, JA; Kreahling, J; Lush, R; Neuger, A; Pinder-Schenck, M; Schell, MJ; Tanvetyanon, T; Tetteh, L; Williams, CC; Zhao, X	1
Wirth, LJ	1
Bansal, N; Center, B; Fetrow, JS; Furdui, CM; Kuremsky, JG; Marrs, GS; Mims, J; Olex, AL; Porosnicu, M; Qian, J; Tsang, AW; Wani, R; Yin, L; Zhao, W	1
Adejumo, O; Allak, A; Hubbard, MA; Jameson, MJ; Khalil, AA; Maxwell, AK; Mendez, RE; Schoeff, SS; VanKoevering, KK	1
Argiris, A; Bauman, JE; Chiosea, S; Conrads, TP; Denq, W; Ferris, RL; Flint, MS; Gooding, WE; Grandis, JR; Gross, ND; Hood, BL; Johnson, JT; Kim, S; Nikiforova, MN; Siegfried, JM; Sun, M; Thomas, SM; Wang, L; Wirth, L	1
Chiara, MD; de Santa-María, IS; Merlo, A; Secades, P; Suarez, C	1
Blackman, A; Clement, PM; Cohen, EEW; Cupissol, D; Degardin, M; Del Campo, JM; Ehrnrooth, E; Fayette, J; Hitt, R; Seiwert, TY; Zhang, W	1
Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M	1
Carroll, WR; Chung, TK; Clemons, L; Desmond, R; Nabell, L; Rosenthal, EL	1
Benaich, N; Huang, Y; Kwok, HF; Murphy, G; Tape, C	1
Corsten, M; Dayekh, K; Dimitroulakos, J; Johnson-Obaseki, S; Sekhon, HS; Villeneuve, PJ; Weberpals, JI	1
Baay, M; Boeckx, C; Deschoolmeester, V; Lardon, F; Limame, R; Op de Beeck, K; Pauwels, P; Peeters, M; Specenier, P; Van Camp, G; Vermorken, JB; Wouters, A; Zwaenepoel, K	1
Chen, CR; Cohen, EW; Frank, SJ; Heymach, JV; Hirsch, FR; Jimeno, A; Lin, H; Lowe, ES; Myers, JN; Nedzi, L; Papadimitrakopoulou, VA; Raben, D; Tran, HT; Vasselli, JR	1
Bourhis, JP; Burtness, B; Cohen, EE; Harrington, KJ; Vermorken, JB	1
Baum, A; Cohen, EE; Grushko, TA; Hardeman, A; Liu, J; Olopade, OI; Solca, F; Soneru, C; Young, NR	1
Atoyan, R; Bauman, JE; Burtness, B; Colevas, AD; Galloway, TJ; Gilbert, J; Jimeno, A; Ma, AW; Mehra, R; Raben, D; Saba, NF; Wang, J; Wirth, LJ	1
Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y	1
Espinosa-Cotton, M; Koch, AT; Love-Homan, L; Simons, AL; Stanam, A	1
Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP	1
Bill, A; Bonenfant, D; Duvvuri, U; Gaither, LA; Gutierrez, A; Kemp, C; Kulkarni, S; Voshol, H	1
Argiris, A	1
Caponigro, F; Clement, PM; Cohen, EE; Cong, XJ; Cupissol, D; de Castro, G; de Souza Viana, L; Del Campo, JM; Ehrnrooth, E; Fayette, J; Gauler, T; Grau, JJ; Guigay, J; Haddad, RI; Keilholz, U; Licitra, LF; Machiels, JP; Tahara, M; Vermorken, JB	2
Killock, D	1
Bourhis, J; Economopoulou, P; Psyrri, A	1
Datta, J; Lang, JC; Mapp, AK; Pan, Q; Piao, L; Teknos, TN; Xie, X; Zhang, M	1
Ahmed, N; Amonkar, M; Biswas-Baldwin, N; Bourhis, J; D'Cruz, A; D'Onofrio, I; Dietzsch, S; Dubinsky, P; El-Hariry, I; Ellis, C; Farrell, J; Franklin, N; Harrington, K; Holeckova, P; Horvath, Z; Jain, M; Legenne, P; Manikhas, G; Mehanna, H; Netherway, T; Santillana, S; Sun, Y; Temam, S; Wang-Silvanto, J; Wissel, P	1
Bonerigo, S; Chung, CH; Cmelak, A; Gilbert, J; John, P; Kang, H; Kiess, A; Marur, S; Murphy, BA; Quon, H; Rudek, MA; Tsottles, N; Veasey, A	1
Brands, RC; De Donno, F; Hartmann, S; Kübler, AC; Linz, C; Müller-Richter, UD; Mutzbauer, G; Seher, A	1
Bernards, R; Brunen, D; de Bree, R; Koole, K; Lieftink, C; Noorlag, R; van Es, RJ; van Kempen, PM; Willems, SM	1
Mehra, R; Zibelman, M	1
Specenier, P; Vermorken, J	1
Bagley, S; Bauml, J; Cohen, RB; Hayes, DN; Hwang, WT; Langer, C; Olson, JG; Weiss, JM	1
Banno, E; de Velasco, MA; Fujita, Y; Hamada, S; Hayashi, H; Nakahara, H; Nakamura, Y; Nishio, K; Nutahara, K; Okegawa, T; Sakai, K; Terashima, M; Togashi, Y; Tomida, S	1
Fan, Z; Li, X; Lu, H; Lu, Y; Qiu, S	1
Baba, Y; Fujii, M; Kato, Y; Maeda, T; Suzuki, A; Takada, S	1
Peng, H; Xia, L; Xiaoli, Z; Zhiqiang, L	1
Chen, Z'; Khuri, FR; Lee, JE; Shin, DM; Shin, HJ; Tighiouart, M; Yang, CS; Zhang, H; Zhang, X	1
Bozec, A; Brunstein, MC; Etienne-Grimaldi, MC; Fischel, JL; Milano, G; Sudaka, A	1
Adamo, V; Caponigro, F; Franchin, G; Mari, E; Milano, A; Morrica, B; Pepe, S; Romano, C; Solla, R	1
Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Sano, D; Taguchi, T; Toth, G; Tsukuda, M	1
Agulnik, M; Wang, LX	1
Agulnik, M; Brockstein, B; Lacouture, M	1
Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H	1
Abidoye, O; Salgia, R; Sattler, M	1
Homes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Lindeman, N; Rogers, AM; Yonesaka, K; Zejnullahu, K; Zhao, F	1
Le, QT; Raben, D	1
Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C	1
Choi, W; Haddad, Y; McConkey, DJ	1
Bourhis, J; D'Ambrosio, C; Deutsch, E; El-Hariry, IA; Harrington, KJ; Holford, CS; Lusinchi, A; Matthews, J; Nutting, CM; Pandeshwara, JS; Rosine, D; Tanay, M; Turner, SJ	1
Armstrong, EA; Benavente, S; Chi, A; Harari, PM; Hsu, KT; Huang, S; Wheeler, DL	1
Barbachano, Y; Box, C; Chambers, P; Eccles, SA; Harrington, KJ; Nutting, CM; Rhŷs-Evans, P; Rogers, SJ; Workman, P	1
Blair, E; Clark, JI; Cohen, EE; Dancey, JE; Davis, DW; Dekker, A; Karrison, TG; Kozloff, MF; Liu, W; Nattam, S; Pierce, C; Seiwert, TY; Stenson, K; Vokes, EE; Wong, SJ; Yan, DH	1
Brizel, DM	1
Ikeda, K; Itoh, S; Matsumoto, F; Ohba, S	1
Burris, HA; Greco, FA; Hainsworth, JD; Kuzur, M; Lunin, S; Markus, TM; Shipley, D; Spigel, DR	1
Armour, A; Cohen, EE; Garin, AM; Ghiorghiu, S; Hargreaves, L; Hirsch, FR; Khorprasert, C; Licitra, L; Rischin, D; Soulieres, D; Speake, G; Stewart, JS; Swaisland, A; Van Herpen, CM; Varella-Garcia, M; Vodvarka, P; Vokes, EE	1
Allen, CT; Calvo, KR; Chen, Z; Dabir, B; Friedman, J; Morris, JC; Mundinger, GS; Pernas, FG; Saigal, K; Van Waes, C; Winters, ME; Xu, X; Yan, B	1
Cohen, EE; Cooper, JB	1
Chen, ZG; Ferris, RL; Grandis, JR; Ming, L; Sun, Q; Thomas, SM; Wang, Y; Yu, J; Zhang, L	1
Chen, ZG; Huang, DH; Khuri, FR; Peng, XH; Shin, DM; Su, L; Zhang, H	1
Li, T; Perez-Soler, R	1
Amin, AR; Chen, ZG; Khuri, FR; Shin, DM	1
Benlyazid, A; Chatelut, E; Delord, JP; Hennebelle, I; Lefebvre, JL; Malard, L; Rochaix, P; Sarini, J; Thomas, F; White-Koning, M	1
Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R	1
Hata, R; Imagawa-Ishiguro, Y; Ito, S; Kato, Y; Komori, R; Kubota, E; Maehata, Y; Ozawa, S; Ozono, S; Shiiki, N; Taguchi, T; Tsukinoki, K; Tsukuda, M	1
Cai, Q; Freilino, ML; Grandis, JR; Hahm, ER; Johnson, DE; Joyce, SC; Leeman-Neill, RJ; Li, C; Neill, DB; Panahandeh, MC; Seethala, RR; Sen, M; Singh, SV; Thomas, SM; Wheeler, SE	1
Allen, CT; Chen, Z; Citrin, D; Colevas, AD; Dancey, J; Gius, D; Harold, NA; Morris, JC; Muir, C; Nottingham, L; Rudy, S; Singh, AK; Van Waes, C	1
Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M	1
Anderton, J; Barlaam, B; Beck, S; Callis, R; Davenport, S; Grosios, K; Hickinson, DM; Klinowska, T; Marshall, G; Mills, E; Ogilvie, D; Smith, P; Speake, G; Trigwell, C; Vincent, J; Wilkinson, RW	1
Bozec, A; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Milano, G	1
Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Takahashi, H; Toth, G; Tsukuda, M	1
Ahsan, A; Bhojani, MS; Hegde, A; Helman, A; Hiniker, SM; Lawrence, TS; Menawat, R; Nyati, MK; Nyati, S; Ramanand, SG	1
Bulj, TK; Cetner, AS; Krunic, AL; Villano, JL	1
Burtness, B; Chen, C; Cohen, R; Feigenberg, SJ; Jimeno, A; Kane, M; Lango, M; Mehra, R; Nicolaou, N; Raben, D; Ridge, J; Rusthoven, KE; Song, JI; Swing, R	1
Arbiser, JL; Bhola, NE; Cai, Q; Grandis, JR; Joyce, SC; Leeman-Neill, RJ; Neill, DB; Thomas, SM	1
Araújo, CM; Bezerra, M; Dias, FL; Federico, MH; Ferreira, CG; Fontão, K; Herchenhorn, D; Knust, RE; Martins, RG; Small, I; Viegas, CM	1
Acheson, KL; Beran, GJ; Bunn, PA; Cassidy, AM; French, T; Graham, A; Hickinson, DM; Hirsch, FR; Holloway, BR; Marshall, GB; McCormack, RM; McWalter, G; Mills, EA; South, MC; Speake, G; Varella-Garcia, M	1
Amornphimoltham, P; Chiorini, JA; Gutkind, JS; Schmidt, M; Weller, ML; Wilson, PA	1
Agrawal, A; Aimiumu, J; Chan, KK; Chen, P; Cheng, H; Dancey, J; Grever, MR; Kraut, EH; Lang, J; Rhoades, C; Young, DC; Zhang, Y	1
Blair, EA; Brockstein, B; Cohen, EE; Dekker, A; Dignam, JJ; Grushko, TA; Haraf, DJ; Kunnavakkam, R; Lester, EP; Lingen, MW; Olopade, OI; Salama, JK; Stenson, KM; Vokes, EE; Williams, R; Witt, ME	1
Andrews, GA; Fooshee, DR; Frederick, MJ; Galer, C; Milas, ZL; Morrow, PK; Myers, JN; Sano, D; Zhao, M	1
Allal, BC; Brillouet, S; Canal, P; Caselles, O; Courbon, F; Delord, JP; Filleron, T; Rochaix, P; Thomas, F; Vergez, S	1
Ferris, RL; Ferrone, S; Grandis, JR; Sharafinski, ME	1
Mandic, R; Meissner, W; Rüddel, J; Wennekes, VE; Werner, JA	1
Grazioso Russi, E; Numico, G; Silvestris, N	1
Collins, DJ; del Campo, JM; DeSouza, NM; Diaz de Corcuera, I; El-Hariry, IA; Harrington, K; Koh, DM; Leach, MO; Orton, MR; Parera, M; Schmid, VJ; Whitcher, B	1
Chen, CT; Genden, EM; Gupta, V; Gurudutt, V; Kao, J; Misiukiewicz, K; Packer, SH; Rivera, M; Teng, M; Tong, CC	1
Krohn, V; Mandic, R; Werner, JA; Wiegand, S	1
Baxi, S; Carlson, D; Fury, MG; Haque, S; Kelly, KW; Lipson, BL; Pfister, DG; Shen, R; Stambuk, H	1
Ferreira, CG; Herchenhorn, D	1
Hanna, EY; Heymach, J; Matsumoto, F; Milas, L; Molkentine, DP; Myers, JN; Papadimitrakopoulou, V; Sano, D; Takahashi, Y; Valdecanas, DR; Zhao, M	1
Argyle, DJ; Bergkvist, GT; Muirhead, R; Pang, LY; Yool, DA	1
Goswami, P; Kalen, AL; Miller, FJ; Orcutt, KP; Parsons, AD; Scarbrough, PM; Sibenaller, ZA; Simons, AL; Sobhakumari, A; Spitz, DR; Wilke, WW; Zhu, Y	1
Hopper, C; Jerjes, W; Mahil, J; Sudhoff, H; Upile, T	1
Gooding, WE; Grandis, JR; Gubish, CT; Siegfried, JM; Stabile, LP; Xu, H	1
Chatelut, E; Civade, E; Delord, JP; Geoerger, B; Hennebelle, I; Le Deley, MC; Thomas, F; Vassal, G; White-Koning, M	1
Bruzzese, F; Budillon, A; Caraglia, M; Carbone, C; Di Gennaro, E; Leone, A; Piro, G; Rocco, M	1
Baumann, M; Bütof, R; Deuse, Y; Eicheler, W; Grenman, R; Gurtner, K; Krause, M; Oertel, R; Schaal, K; Thames, H; Yaromina, A	1
Ang, MK; Baskaran, N; Goh, C; Hui, KM; Hwang, J; Khoo, ML; Lim, A; Lim, TH; Lim, WT; Ng, QS; Soo, KC; Tan, DS; Tan, EH; Tan, PH; Tan, SH; Tan, T; Teng, YH	1
Arias de la Vega, F; Arrazubi, V; Calvo, FA; Contreras, J; de la Torre, A; de Las Heras, M; García-Saenz, JA; Herruzo, I; Prieto, I; Romero, J	1
Chen, C; D'Cruz, AK; Fijuth, J; Gregoire, V; Hamoir, M; Julka, PK; Kane, M; Kawecki, A; Korzeniowski, S; Kumar, RR; Machiels, JP; Prasad, S; Raben, D; Radosevic-Jelic, L; Sellers, MV; Tchakov, I; Wang, HM	1
Biswas-Baldwin, N; Bourhis, J; Carracedo, C; Compton, N; Cupissol, D; De Raucourt, D; Del Campo, JM; Downie, L; El-Hariry, I; Harrington, KJ; Hitt, R; Lokanatha, D; Maroudias, N; Midwinter, D; Nutting, CM; Sebastian, P; Temam, S	1
Arnold, W; Beck, C; Boulesteix, AL; Knopf, A; Margraf, J; Pickhard, AC; Pigorsch, S; Piontek, G; Reiter, R; Scherer, EQ; Schlegel, J; Stark, T	1
Chen, ZG; Huang, D; Shin, DM; Su, L; Wang, D; Zhang, H	1
Liebmann, C; Weisheit, S	1
Barboriak, DP; Brizel, DM; Carroll, MD; Cleland, E; Craciunescu, OI; MacFall, JR; Muradyan, N; Yoo, DS	1
Adelstein, DJ; Ives, DI; Michal, SA; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG	1
Adelstein, DJ; Ives, DI; Lorenz, RR; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG	1
Agulnik, M	1
Brizel, DM; Broadwater, G; Carroll, MD; Clough, R; Craciunescu, O; Dunphy, FR; Esclamado, RM; Hoang, J; Kirkpatrick, JP; MacFall, JR; Peterson, BL; Ready, NE; Scher, RL; Yoo, DS	1
Chambers, MS; El-Naggar, AK; Feng, L; Glisson, BS; Lewis, CM; Lustig, RA; Rosenthal, DI; Tang, X; Wan, F; Weber, RS; Wistuba, II	1
Bienvenu, S; Chaudhry, MA; Forastiere, A; Gilbert, J; Gillison, M; Higgins, MJ; Rudek, MA; Tsottles, N; Wahl, R; Zhao, M	1
Ahn, SM; Christopoulos, A; Gooding, WE; Grandis, JR; Kim, S; Klein, JD	1
Fujii, M; Hasegawa, Y; Ijichi, K; Kondo, E; Maseki, S; Murakami, S; Nakanishi, H; Ogawa, T; Tanaka, H	1
Argyle, DJ; Bergkvist, GT; Cervantes-Arias, A; Muirhead, R; Pang, LY; Yool, DA	1
Aktolga, S; Blair, EA; Bozeman, J; Cohen, EE; Dancey, JE; Davis, DW; de Souza, JA; Khattri, A; Kozloff, MF; Kunnavakkam, R; Lingen, MW; Nattam, S; Seiwert, TY; Stenson, KM; Vokes, EE; Wong, SJ; Zhang, Y	1
Abhold, EL; Altuna, X; Blair, KJ; Brumund, KT; Haas, M; Kiang, A; Kuo, SZ; Lopez, JP; Ongkeko, WM; Patel, A; Rahimy, E; Wang-Rodriguez, J; Weisman, RA; Yu, MA	1
Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N	1
Chang, X; Chatterjee, A; Horii, A; Kobayashi, T; Koch, WM; Kusuke, D; Levenson, VV; Liggett, TE; Melnikov, AA; Monitto, CL; Ogawa, T; Shiga, K; Sidransky, D	1
Clayburgh, DR; Gross, ND; Koide, J; Proby, C; Wong, MH	1
Aiba, S; Fujimura, T; Haga, T; Hashimoto, A; Hidaka, T; Mizuashi, M; Onami, K; Watabe, A	1
Agulnik, M; Blair, EA; Cohen, EE; Dekker, A; Grushko, TA; Olopade, OI; Perez, CA; Raez, LE; Seiwert, TY; Song, H; Stenson, K; Vokes, EE	1
Dittmann, K; Huber, SM; Mayer, C; Misovic, M; Rodemann, HP	1
Abemayor, E; Dennis, M; Dohadwala, M; Dubinett, SM; Elashoff, DA; Lin, Y; Luo, J; Sharma, S; St John, MA; Wang, G	1
Argiris, A; Ferris, RL; Freilino, ML; Gooding, WE; Grandis, JR; Gross, N; Moskowitz, HS; Thomas, SM	1
Grandis, JR; Quesnelle, KM; Ratay, MK; Wheeler, SE	1
Benlyazid, A; Delmar, P; Delord, JP; Hennebelle, I; McLoughlin, P; Rochaix, P; Sarini, J; Thomas, F; Vergez, S	1
Gooding, WE; Grandis, JR; Johnson, DE; Joyce, S; Li, C; Maxwell, J; Panahandeh, M; Sen, M; Thomas, SM; Wang, L	1
Baldi, A; Citro, G; Fanciulli, M; Spugnini, EP	1
Boehm, A; Diet, A; Dietz, A; Mozet, C; Reiche, A; Schrader, C; Wichmann, G	1
Bensadoun, RJ; Bertucci, F; Cayre, A; Dassonville, O; De Raucourt, D; Etienne-Grimaldi, MC; Finetti, P; Geoffrois, L; Giraud, P; Grall, D; Milano, G; Morinière, S; Penault-Llorca, F; Racadot, S; Sudaka, A; Thariat, J; Van Obberghen-Schilling, E	1
Clement, PM; Cools, J; Gutkind, JS; Hoeben, A; Martin, D	1
Ahsan, A; Bradford, CR; Chepeha, DB; D'Silva, N; Eisbruch, A; Helman, JI; Lawrence, TS; Nyati, MK; Ramanand, SG; Tsien, CI; Wolf, GT; Worden, FP	1
Busch, TM; Cengel, KA; Edmonds, C; Gallagher-Colombo, SM; Hagan, S	1
Johansson, AC; La Fleur, L; Roberg, K	1
Ali, A; Candy, PA; Epis, MR; Ganda, C; Giles, KM; Kalinowski, FC; Leedman, PJ; Webster, RJ	1
Fletcher, EV; Knudson, CM; Love-Homan, L; Martin, SM; Parsons, AD; Simons, AL; Sobhakumari, A; Spitz, DR	1
Amler, LC; Armstrong, EA; Harari, PM; Huang, S; Li, C; Peet, CR; Saker, J; Sliwkowski, MX	1
Carroll, WR; Clemons, L; Deep, NL; Desmond, R; Heath, CH; Magnuson, JS; Nabell, L; Rosenthal, EL; Spencer, S	1
Cohen, EE; Grushko, T; Liu, J; Liu, W; Olopade, OI; Pierce, C; Seiwert, TY; Shen, C; Wei, TF; Young, NR	1
Grandis, JR; Gubish, CT; He, G; Henry, C; Joyce, S; Lui, VW; Quesnelle, KM; Siegfried, JM; Stabile, LP; Thomas, S	1
Barr, S; Cassell, A; Freilino, ML; Grandis, JR; Lee, J; Panahandeh, MC; Thomas, SM; Wang, L	1
Berrier, A; Biswas-Baldwin, N; Compton, N; de Mendoza, FH; El-Hariry, I; Fayette, J; Franklin, N; Harrington, K; Housset, M; Kumar, R; Lau, M; Legenne, P; Mehanna, H; Remenar, E; Robinson, M	1
Alba, E; Álvarez, M; de Luque, V; González-Hermoso, C; Jerez, JM; Medina, JA; Pajares, B; Rueda, A; Toledo, MD; Trigo, JM	1
Casás-Selves, M; DeGregori, J; Hatheway, C; Heasley, LE; Hinz, TK; Kim, J; Marek, LA; Singleton, KR; Tan, AC	1
Arias-Pulido, H; Bauman, JE; Bishop, J; Chung, CH; Fekrazad, MH; Fertig, E; Howard, J; Jones, DV; Lee, SJ; Olson, GT; Ozawa, H; Spafford, MJ; Wang, H	1
Armstrong, EA; Harari, PM; Huang, SM; Li, J	1
Ranson, M	1
Averbuch, SD; Baselga, J; Herbst, RS; Hong, WK; LoRusso, PM; Maddox, AM; Ochs, J; Rojo, F; Rothenberg, ML; Rubin, EH; Small, EJ; Swaisland, H	1
Avallone, A; Caponigro, F; Comella, G; Comella, P; De Lucia, L; De Rosa, P; De Rosa, V; Rosati, G	1
Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H	1
Gschwind, A; Prenzel, N; Ullrich, A	1
Baselga, J; Hammond, LA	1
Abbruzzese, A; Avallone, A; Barbarino, M; Bruzzese, F; Budillon, A; Caponigro, F; Caraglia, M; Comella, P; De Lorenzo, S; Di Gennaro, E; Pepe, S	1
Lorusso, PM	1
Cohen, EE; Huo, D; Recant, W; Rosen, F; Stadler, WM; Stenson, K; Vokes, EE	1
Amornphimoltham, P; Gutkind, JS; Nelkin, BD; Park, JI; Patel, V; Sriuranpong, V	1
Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Francoual, M; Magné, N; Milano, G; Renée, N; Tiffon, C	1
Hamakawa, H; Kayahara, H; Kiyota, A; Mihara, M; Nakashiro, K; Shintani, S; Sumida, T	1
Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Magné, N; Marchetti, S; Milano, G; Renée, N; Tiffon, C	1
Burgess, AW; Johns, TG; Jungbluth, AA; Luwor, RB; Murone, C; Nice, EC; Old, LJ; Perera, RM; Scott, AM; Stockert, E; Vitali, AA; Walker, F; Weinstock, J	1
Pérez-Soler, R	1
Agarwala, SS; Hidalgo, M; Senzer, NN; Siu, LL; Soulieres, D; Vokes, EE	1
Adam, L; Bagheri-Yarmand, R; Barnes, CJ; Clayman, GL; El-Naggar, A; Hong, WK; Kumar, R; Lotan, R; Papadimitrakopoulou, VV; Wang, RA; Yang, Z	1
Ochs, JS	1
Caponigro, F	1
Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S	1
Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X	1
Bjarnason, GA; Charpentier, D; Dent, S; Douglas, L; Goel, R; Matthews, S; Seymour, L; Walsh, W; Winquist, E; Wong, R	1
Cole, IE; Gallagher, RM; Kalish, LH; Kwong, RA; Musgrove, EA; Sutherland, RL	1
Von Pawel, J	1
Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C	1
Arnheim, K	1
Fenyo, D; Gibson, N; Griffin, G; Haley, JD; Hunt, T; Iwata, K; Petti, F; Settinari, T; Thelemann, A	1
de Jong, M; Jansen, P; Kerrebijn, J; Planting, A; Smith, M; Verweij, J	1
Al-Hazzaa, A; Birchall, MA; Bowen, ID; Randerson, P	1
Baibakov, G; Emmert-Buck, MR; Gutkind, JS; Knezevic, V; Patel, V; Ramesh, A; Traicoff, JL	1
Dannenberg, AJ; Gibson, N; Lippman, SM; Subbaramaiah, K	1
Chen, A; Chen, ZG; Choe, MS; Khuri, FR; Lin, Y; Shin, DM; Shin, HJ; Sun, SY; Wieand, HS; Zhang, X	1
Haddad, RI; Joshi, VA; Lee, JC; Lindeman, NI; Norris, CM; Posner, MR; Wirth, LJ; Zhao, X	1
Bell, DW; Brannigan, BW; Clark, JR; Cohen, EE; Dahiya, S; Haber, DA; Harris, PL; Haserlat, SM; Lingen, MW; Martin, LE; Muir, B; Okimoto, RA; Rocco, JW; Sgroi, DC; Vokes, EE	1
Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S	1
Brockstein, BE; Cohen, EE; Dekker, A; Huo, D; Kane, MA; List, MA; Mauer, AM; Mehrotra, B; Pierce, C; Vokes, EE	1
Chai, RL; Grandis, JR	1
Harari, PM; Huang, S	1
Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Nyati, MK; Scheurer, AM	1
Arra, C; Avallone, A; Bruzzese, F; Budillon, A; Caraglia, M; Di Gennaro, E; Pepe, S; Tagliaferri, P	1
A'Hern, RP; Box, C; D'Ambrosio, C; Eccles, SA; Harrington, KJ; Kirby, AM; Nutting, CM; Rogers, SJ; Syrigos, KN; Tanay, M	1
Cerniglia, G; Gupta, A; Jiang, Z; Kao, GD; Maity, A; Pore, N	1
Aguilera, J; Altuna, X; Chen, JS; Chu, TS; Lopez, JP; Ongkeko, WM; Pardo, FS; Wang-Rodriguez, J; Weisman, RA	1
Hennemann, B	1
Khuri, FR; Saba, NF; Shin, DM	1
Fish-Steagall, A; Searcy, P; Sipples, R	1
Cohen, EE	1
Bogeschdorfer, F; Gronau, S; Riechelmann, H	1
Elenius, K; Erjala, K; Grenman, R; Junttila, TT; Kulmala, J; Mali, P; Pulkkinen, J; Savisalo, M; Sundvall, M; Zhang, N	1
Bette, M; Folz, BJ; Mandic, R; Neubauer, A; Rodgarkia-Dara, CJ; Weihe, E; Werner, JA; Zhu, L	1
Bozec, A; Fischel, JL; Formento, P; Gugenheim, J; Hofman, P; Lassalle, S; Milano, G	1
Erjala, K; Grénman, R; Kulmala, J; Raitanen, M	1
Fujita, K; Ishiguro, Y; Kawakami, M; Kimura, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M; Yamashita, Y	1
Eckardt, A; Morgan, MA; Reuter, CW	1
Baillargeon, GM; Calvo, E; Chin, SF; Hidalgo, M; Irish, J; Kreisberg, JI; Malik, SN; Rowinsky, EK; Santabarbara, P; Siu, LL	1
Chan, A; Chen, R; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P; Wheelhouse, J; Zhang, X	1
Frederick, B; Gustafson, DL; Merz, AL; Raben, D	1
Bhola, NE; Grandis, JR; Gubish, CT; Lui, VW; Mills, GB; Shin, D; Siegfried, JM; Siwak, DR; Thomas, SM; Zhang, Q	1
Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Li, X; Lopez, CA; Normolle, DP; Nyati, MK; Varambally, S	1
Chen, Z; Choe, MS; Klass, CM; Shin, DM; Zhang, X	1
Burtness, BA; Forastiere, AA	1
Chen, EX; Chin, SF; Dancey, J; Eisenhauer, EA; Francis, P; Harvey, L; Klein, M; Pond, GR; Siu, LL; Soulieres, D; Winquist, E; Zhang, W	1
Agulnik, M; Chen, EX; Chen, H; Chen, S; da Cunha Santos, G; Dancey, J; Dos Reis, PP; Hedley, D; Ho, J; Kamel-Reid, S; Marrano, P; Nicklee, T; Pond, GR; Shyr, Y; Siu, LL; Soulieres, D; Squire, JA; Tsao, MS; Winquist, E	1
Bunn, PA; Chan, D; Coldren, CD; Frederick, BA; Helfrich, BA; Raben, D; Zheng, D	1
Avallone, A; Bruzzese, F; Budillon, A; Caraglia, M; Comella, P; Delrio, P; Di Gennaro, E; Laus, G; Pepe, S	1
Bozec, A; Formento, P; Hofman, P; Lassalle, S; Lippens, C; Milano, G	1
Argiris, A; Grandis, JR; Karamouzis, MV	1
Gyergyay, F	1
Tsukuda, M	1
Daly, RJ; Lehrbach, GM; Musgrove, EA; Sutherland, RL; Timpson, P; Wilson, AS	1
Elenius, K; Erjala, K; Grénman, R; Kulmala, J; Sundvall, M; Zhang, N	1
Baron, A; Campana, J; Chen, C; Dancey, J; Eckhardt, SG; Harrison, L; Hu, K; Kane, M; Quon, H; Raben, A; Raben, D; Said, S; Song, J	1
Chen, EX; Chia, S; Colevas, AD; Hotte, SJ; Johnson, C; Pond, GR; Schwarz, JK; Siu, LL; Synold, TW; Tang, PA; Vasist, LS; Winquist, E	1
Allal, BC; Benlyazid, A; Chatelut, E; Courbon, F; Delord, JP; Lefebvre, JL; Rives, M; Rochaix, P; Sarini, J; Thomas, F	1
Imagawa-Ishiguro, Y; Kato, Y; Sano, D; Taguchi, T; Tsukuda, M	1
Atkinson, DM; Carlson, BL; Clarke, MJ; Jacobson, MS; Kemp, BJ; Lowe, VJ; Mladek, AC; Sarkaria, JN; Trump, DP	1
Armstrong, DK; Brahmer, JR; Carducci, MA; Chen, P; Das, S; Desai, A; Fackenthal, DL; Fleming, GF; Janisch, L; Jiang, X; Karrison, T; Liu, W; Poonkuzhali, B; Ramirez, J; Ratain, MJ; Rudin, CM; Schuetz, E; Vokes, EE	1
Boehm, AL; Freilino, M; Gooding, WE; Grandis, JR; Johnson, DE; Seethala, R; Sen, M; Wang, S; Wong, SM	1
Glisson, BS; Johnson, FM; Saigal, B	1
Accardi, R; Azzariti, A; Conti, D; LaCalamita, R; Paradiso, A; Pilato, B; Porcelli, L; Sebastian, S; Simone, GM; Tommasi, S; Tommasino, M	1
Chen, G; Rosowsky, A; Wright, JE	1
Cheson, BD; Phillips, PH; Sorensen, JM	1
Affleck, K; Dean, C; Modjtahedi, H; Stubberfield, C	1
Ara, G; Chen, YN; Coleman, CN; Recht, A; Teicher, BA	1
Cao, S; McGuire, JJ; Rustum, YM	1
Azrak, RG; Cao, S; Guo, B; Rustum, YM; Tóth, K; Yin, MB	1
Arnold, LD; Baker, DA; Barbacci, EG; Davis, JA; Doty, JL; Iwata, KK; Morin, MJ; Moyer, JD; Pollack, VA; Pustilnik, LR; Savage, DM; Sloan, DE; Smolarek, TA; Tsaparikos, KE; Vaidya, MP	1
Canestrari, JG; McGuire, JJ; Nagel, GS	1
Avallone, A; Blackie, R; Budillon, A; Caponigro, F; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Gravina, A; McLeod, H; Morsman, J	1
Azrak, RG; Cao, S; Guo, B; Rustum, YM; Tóth, K	1
Clarke, SJ; Dalley, D; Davidson, YE; Green, M; Mitchell, PL; Olver, I; Rischin, D; Zalcberg, J	1
Boddy, AV; Calvert, AH; Griffin, MJ; Hughes, AN; Johnston, A; Kerr, B; Lee, C; Liang, B; Newell, DR	1
Avallone, A; Budillon, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Di Gennaro, E; Ionna, F; Manzione, L; Mozzillo, N; Rivellini, F	1
Avallone, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Ionna, F; Rivellini, F	1
Baatenburg de Jong, RJ; Keizer, HJ; ten Bokkel Huinink, D; Tesselaar, ME; Verschuur, HP	1
Avallone, A; Budillon, A; Caponigro, F; Comella, G; Comella, P	1
Albanell, J; Anido, J; Baselga, J; Codony-Servat, J; Del Campo, JM; Giralt, J; Mendelsohn, J; Nicholson, RI; Raspall, G; Rojo, F; Roselló, J; Sauleda, S	1
Norman, P	1
Belpomme, D; Clendeninn, N; Domenge, C; Humblet, Y; Johnston, A; Kelly, C; Penning, C; Pivot, X; Ruxer, R; Schneider, M; Stern, J; Tortochaux, J; Wadler, S	1
Dubreuil, A; Fischel, JL; Formento, P; Lagrange, JL; Magné, N; Marcié, S; Milano, G	1
Bunn, PA; Chan, D; Helfrich, BA; Johnson, G; Raben, D	1
Dubreuil, A; Fischel, JL; Formento, P; Laurent-Puig, P; Magné, N; Milano, G; Poupon, MF	1
Bertino, JR; Chang, YM; McGuire, JJ; Pizzorno, G	1
Robert, F	1

Reviews

36 review(s) available for quinazolines and Cancer of Head

Article	Year
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials. Respiratory medicine, 2013, Volume: 107, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors	2013
Afatinib in the treatment of head and neck squamous cell carcinoma. Expert opinion on investigational drugs, 2014, Volume: 23, Issue:1 Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2014
Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2015 Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Early Detection of Cancer; Head and Neck Neoplasms; Humans; Immunotherapy; Meta-Analysis as Topic; Methotrexate; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Papillomavirus Vaccines; Postoperative Care; Precision Medicine; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck; Therapies, Investigational	2015
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. American journal of clinical oncology, 2016, Volume: 39, Issue:4 Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus	2016
Afatinib in squamous cell carcinoma of the head and neck. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:9 Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Methotrexate; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2016
The role of inhibitors of the epidermal growth factor in management of head and neck cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 2008, Volume: 6, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Quinazolines	2008
EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2008
EGFR-targeted therapeutics: focus on SCCHN and NSCLC. TheScientificWorldJournal, 2008, Sep-21, Volume: 8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines	2008
Integrating biologically targeted therapy in head and neck squamous cell carcinomas. Seminars in radiation oncology, 2009, Volume: 19, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Lapatinib; Quinazolines	2009
Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head & neck, 2009, Volume: 31, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Signal Transduction; Treatment Outcome	2009
Skin toxicities associated with epidermal growth factor receptor inhibitors. Targeted oncology, 2009, Volume: 4, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Head and Neck Neoplasms; Humans; Mice; Pancreatic Neoplasms; Patient Education as Topic; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Vitamin K 3	2009
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head & neck, 2010, Volume: 32, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines	2010
Advances in EGFR-directed therapy in head and neck cancer. Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis	2011
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2012
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2012, Volume: 269, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles	2012
Preclinical models in electrochemotherapy: the role of veterinary patients. Future oncology (London, England), 2012, Volume: 8, Issue:7 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cat Diseases; Cats; Cisplatin; Dog Diseases; Dogs; Drug Evaluation, Preclinical; Electrochemotherapy; Epirubicin; Head and Neck Neoplasms; Melanoma; Mitoxantrone; Neoplasms; Quinazolines; Sarcoma; Thiophenes	2012
ZD1839 (Iressa): for more than just non-small cell lung cancer. The oncologist, 2002, Volume: 7 Suppl 4 Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome	2002
HER-targeted tyrosine-kinase inhibitors. Oncology, 2002, Volume: 63 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2	2002
Phase I studies of ZD1839 in patients with common solid tumors. Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines	2003
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:11 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome	2003
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. International journal of radiation oncology, biology, physics, 2004, Mar-01, Volume: 58, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents	2004
Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer. Anti-cancer drugs, 2004, Volume: 15, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines	2004
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bulletin du cancer, 2004, May-01, Volume: 91, Issue:5 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines	2004
Advances in molecular diagnostics and therapeutics in head and neck cancer. Current treatment options in oncology, 2006, Volume: 7, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Clinical Trials as Topic; Diagnosis, Differential; DNA Methylation; DNA, Mitochondrial; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microsatellite Repeats; Prognosis; Quinazolines; RNA, Messenger	2006
Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Seminars in radiation oncology, 2006, Volume: 16, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2006
[Palliative chemotherapy of head and neck cancer: present status and future development]. Laryngo- rhino- otologie, 2006, Volume: 85, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine	2006
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2006
Clinical experience with anti-EGFR therapy. Seminars in oncology nursing, 2006, Volume: 22, Issue:1 Suppl 1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome	2006
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Treatment Outcome	2006
[New substances in the therapy of head and neck cancer]. Laryngo- rhino- otologie, 2006, Volume: 85, Issue:7 Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration	2006
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. British journal of cancer, 2007, Feb-12, Volume: 96, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2007
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA, 2007, Jul-04, Volume: 298, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2007
[Head and neck: molecular-targeted therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Head and Neck Neoplasms; Humans; Paclitaxel; Quinazolines	2007
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy. Anti-cancer drugs, 2001, Volume: 12, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Rectal Neoplasms; Thiophenes	2001
OSI-774 OSI Pharmaceuticals. Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:2 Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Oncogenes; Quinazolines; Structure-Activity Relationship	2001
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 4 Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Chemoprevention; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Quinazolines; Signal Transduction; Transplantation, Heterologous; Up-Regulation	2002

Trials

81 trial(s) available for quinazolines and Cancer of Head

Article	Year
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Cancer medicine, 2021, Volume: 10, Issue:20 Topics: Adult; Aged; Class I Phosphatidylinositol 3-Kinases; Drug Administration Schedule; Drug Eruptions; Exanthema; Female; Genes, p53; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Stomatitis; Treatment Outcome; Young Adult	2021
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral oncology, 2019, Volume: 97 Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Adherence and Compliance; Treatment Outcome	2019
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Oct-01, Volume: 28, Issue:10 Topics: Administration, Intravenous; Administration, Oral; Afatinib; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; Disease-Free Survival; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Predictive Value of Tests; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2017
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Mar-01, Volume: 19, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Movement; Cell Proliferation; Cyclooxygenase Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Prognosis; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Tumor Cells, Cultured	2013
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Male; Pain; Quinazolines; Remission Induction; Treatment Outcome	2013
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome	2013
Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib. Onkologie, 2013, Volume: 36, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome	2013
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Xenograft Model Antitumor Assays	2013
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral oncology, 2013, Volume: 49, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Taxoids	2013
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Injections, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Rate; Treatment Outcome	2013
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. British journal of cancer, 2013, Oct-15, Volume: 109, Issue:8 Topics: Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; DNA-Binding Proteins; Endonucleases; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Prospective Studies; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2013
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Disease Progression; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pyrazoles; Quinazolines; Sulfonamides	2014
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Mar-15, Volume: 20, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Panobinostat; Quinazolines; Treatment Outcome	2014
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-15, Volume: 20, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sulindac; Tissue Array Analysis	2014
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:9 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Young Adult	2014
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC cancer, 2014, Jun-28, Volume: 14 Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck	2014
Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients. Annals of surgical oncology, 2014, Volume: 21, Issue:13 Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate	2014
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head & neck, 2016, Volume: 38, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2016
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized control Trials, 2014, Nov-29, Volume: 15 Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Protocols; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design; Risk Factors; Squamous Cell Carcinoma of Head and Neck; Time Factors; Treatment Outcome	2014
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Apr-01, Volume: 21, Issue:7 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; ErbB Receptors; Female; Head and Neck Neoplasms; Histone Deacetylases; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck	2015
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer, 2015, May-15, Volume: 121, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome	2015
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma. Cancer biology & therapy, 2015, Volume: 16, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:5 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2015
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Stu Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-10, Volume: 33, Issue:35 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Double-Blind Method; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; International Cooperation; Kaplan-Meier Estimate; Lapatinib; Maintenance Chemotherapy; Male; Middle Aged; Molecular Targeted Therapy; Odds Ratio; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2015
A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral oncology, 2016, Volume: 53 Topics: Afatinib; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Quinazolines; Treatment Outcome	2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:8 Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2016
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anti-cancer drugs, 2008, Volume: 19, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Quinazolines; Radiotherapy Dosage	2008
High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. American journal of clinical oncology, 2008, Volume: 31, Issue:6 Topics: Adult; Aged; Amines; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Gefitinib; Head and Neck Neoplasms; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Paresthesia; Prognosis; Quinazolines; Radiation Injuries; Radiotherapy; Stomatitis	2008
Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-01, Volume: 27, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2009
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. The Lancet. Oncology, 2009, Volume: 10, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2009
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer, 2009, May-15, Volume: 115, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Remission Induction; Taxoids; Treatment Outcome	2009
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-10, Volume: 27, Issue:11 Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome	2009
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral oncology, 2009, Volume: 45, Issue:10 Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome	2009
Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infections; Lung Diseases, Interstitial; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Paclitaxel; Pilot Projects; Quinazolines; Radiotherapy Dosage; Remission Induction; Stomatitis	2010
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. International journal of radiation oncology, biology, physics, 2010, Nov-15, Volume: 78, Issue:4 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gastrostomy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retreatment; Treatment Outcome	2010
Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. International journal of radiation oncology, biology, physics, 2010, Nov-01, Volume: 78, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Drug Administration Schedule; Drug Eruptions; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Oropharyngeal Neoplasms; Quinazolines; Radiotherapy Dosage; Salvage Therapy; Survival Rate	2010
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Chromatography, Liquid; Docetaxel; Dose-Response Relationship, Drug; Enzyme Induction; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Tandem Mass Spectrometry; Taxoids	2011
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines	2010
A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck. Magma (New York, N.Y.), 2011, Volume: 24, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Bayes Theorem; Biomarkers; Carcinoma, Squamous Cell; Contrast Media; Endpoint Determination; Head and Neck Neoplasms; Humans; Lapatinib; Magnetic Resonance Imaging; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome	2011
Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer, 2011, Jul-15, Volume: 117, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazoles; Quinazolines; Radiation-Sensitizing Agents; Retreatment; Sulfonamides	2011
Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer research, 2011, Volume: 31, Issue:1 Topics: Adult; Aged; Benzodioxoles; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate; Young Adult	2011
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-15, Volume: 17, Issue:14 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Squamous Cell; Child; Child, Preschool; Cytochrome P-450 CYP3A; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Young Adult	2011
Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression; Gene Expression Profiling; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Male; Matrix Metalloproteinase 11; Middle Aged; Oligonucleotide Array Sequence Analysis; Quinazolines; Risk Factors; Smoking; Treatment Outcome	2012
Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines	2012
Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011, Volume: 100, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Double-Blind Method; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2011
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. British journal of cancer, 2011, Aug-23, Volume: 105, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Disease Progression; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Squamous Cell; Placebos; Quinazolines; Single-Blind Method; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2011
Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters. International journal of radiation oncology, biology, physics, 2012, Mar-01, Volume: 82, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Area Under Curve; Bevacizumab; Chemoradiotherapy; Cisplatin; Contrast Media; Erlotinib Hydrochloride; Gadolinium DTPA; Head and Neck Neoplasms; Humans; Image Enhancement; Lymphatic Metastasis; Magnetic Resonance Imaging; Microcirculation; Molecular Targeted Therapy; North Carolina; Quinazolines	2012
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. Head & neck, 2012, Volume: 34, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult	2012
Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-01, Volume: 18, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome	2012
A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-01, Volume: 18, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Skin Neoplasms; Survival Analysis; Treatment Outcome	2012
A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines	2012
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-15, Volume: 18, Issue:8 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2012
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral oncology, 2012, Volume: 48, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Gefitinib; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin	2012
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral oncology, 2012, Volume: 48, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Interleukin-6; Male; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Placebos; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sulindac; Transforming Growth Factor alpha	2012
Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-15, Volume: 18, Issue:18 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Treatment Outcome	2012
Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. International journal of radiation oncology, biology, physics, 2013, Apr-01, Volume: 85, Issue:5 Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Skin Neoplasms; Stomatitis	2013
Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Exanthema; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Male; Middle Aged; Neoplasm Staging; Papillomaviridae; Quinazolines; Radiotherapy Dosage; Treatment Outcome	2013
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral oncology, 2013, Volume: 49, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Platinum; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6 Kinases; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins	2013
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-15, Volume: 20, Issue:18 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases	2002
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study. Oncology, 2002, Volume: 63, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Hematologic Diseases; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Quinazolines; Thiophenes; Treatment Outcome	2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome	2002
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Illinois; Immunohistochemistry; Intubation, Gastrointestinal; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Treatment Outcome	2003
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines	2004
Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). Investigational new drugs, 2005, Volume: 23, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Salvage Therapy; Stomach Neoplasms; Thiophenes	2005
Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:1 Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines; Radiotherapy; Thiophenes	2005
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pyrazoles; Quinazolines; Sulfonamides	2005
Bexarotene and erlotinib for aerodigestive tract cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured	2005
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Salvage Therapy; Survival Rate; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A	2005
Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. British journal of cancer, 2006, Mar-13, Volume: 94, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Survival Analysis	2006
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-01, Volume: 25, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines	2007
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-01, Volume: 25, Issue:16 Topics: Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Skin	2007
Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-01, Volume: 25, Issue:31 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines	2007
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Investigational new drugs, 2008, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Female; Gene Expression; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Kinesins; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Quinazolines; Treatment Outcome	2008
Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Dec-01, Volume: 13, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p21; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Hybridization; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines	2007
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Quinazolines; Thiophenes	1999
Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome	2000
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. British journal of cancer, 2000, Volume: 82, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Drug Monitoring; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Quinazolines; Tumor Cells, Cultured	2000
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG). Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Thiophenes; Treatment Outcome	2000
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours. Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Mitoxantrone; Neoplasms; Quinazolines; Thiophenes	2001
A phase I study of a fixed dose of cisplatin with increasing doses of raltitrexed (Tomudex) in the treatment of patients with locally advanced or metastatic squamous cell carcinoma of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Quinazolines; Thiophenes; Treatment Outcome	2001
Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Diarrhea; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Quinazolines; Thymidylate Synthase; Treatment Outcome	2001

Other Studies

173 other study(ies) available for quinazolines and Cancer of Head

Article	Year
Evaluation of the Efficacy of Saracatinib-Loaded Nanoparticles in Lymphatic Metastases of HNSCC with the Aid of Bioluminescence Imaging. Methods in molecular biology (Clifton, N.J.), 2022, Volume: 2525 Topics: Animals; Benzodioxoles; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Lymphatic Metastasis; Mice; Nanoparticles; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2022
Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma. Journal of hematology & oncology, 2019, 12-05, Volume: 12, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodioxoles; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; src-Family Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2019
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models. Molecular cancer therapeutics, 2020, Volume: 19, Issue:5 Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA-Activated Protein Kinase; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Radiation, Ionizing; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2020
Gold Nanoparticles Enhance EGFR Inhibition and Irradiation Effects in Head and Neck Squamous Carcinoma Cells. BioMed research international, 2020, Volume: 2020 Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gold; Head and Neck Neoplasms; Humans; Metal Nanoparticles; Microscopy, Electron, Transmission; Quinazolines; Spectrum Analysis, Raman; Squamous Cell Carcinoma of Head and Neck; Tyrphostins	2020
Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. Oncotarget, 2017, Mar-28, Volume: 8, Issue:13 Topics: Afatinib; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2017
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas. Anticancer research, 2017, Volume: 37, Issue:6 Topics: Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines	2017
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nature communications, 2017, 09-05, Volume: 8, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice, Inbred NOD; Mouth Neoplasms; Phenotype; Phosphoproteins; Precision Medicine; Quinazolines; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins	2017
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nature medicine, 2017, Volume: 23, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; In Vitro Techniques; Male; Middle Aged; Molecular Targeted Therapy; Mouth Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA Isoforms; RNA Splicing; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays	2017
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells. Oncology reports, 2018, Volume: 39, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Irinotecan; Lysosomes; Mice; Proteolysis; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays	2018
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib. Journal of hematology & oncology, 2018, 06-20, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Benzodioxoles; Disease Models, Animal; Drug Carriers; Enzyme Inhibitors; Head and Neck Neoplasms; Mice; Nanomedicine; Nanoparticles; Neoplasm Metastasis; Quinazolines; Snail Family Transcription Factors; src-Family Kinases; Vimentin	2018
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma. Molecular pharmacology, 2019, Volume: 95, Issue:5 Topics: Afatinib; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides	2019
The Selection of NFκB Inhibitors to Block Inflammation and Induce Sensitisation to FasL-Induced Apoptosis in HNSCC Cell Lines Is Critical for Their Use as a Prospective Cancer Therapy. International journal of molecular sciences, 2019, Mar-15, Volume: 20, Issue:6 Topics: Amides; Anti-Inflammatory Agents; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Fas Ligand Protein; Head and Neck Neoplasms; Humans; Hydrocortisone; Interleukin-8; NF-kappa B; Phenyl Ethers; Pyrimidines; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Tumor Necrosis Factor-alpha	2019
Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. Photodiagnosis and photodynamic therapy, 2019, Volume: 27 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chlorophyllides; DNA Damage; DNA-Activated Protein Kinase; Down-Regulation; Drug Therapy, Combination; ErbB Receptors; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Photochemotherapy; Photosensitizing Agents; Piperidines; Porphyrins; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2	2019
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PloS one, 2013, Volume: 8, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Signal Transduction; Tumor Cells, Cultured	2013
Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8 Topics: Animals; Benzamides; beta Karyopherins; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Genes, Essential; Genome-Wide Association Study; Head and Neck Neoplasms; Humans; Kinesins; Lung Neoplasms; Mice; Microtubule-Associated Proteins; Nuclear Proteins; Quinazolines; ran GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays	2013
Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck. Oral oncology, 2013, Volume: 49, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sirolimus	2013
Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib. Molecular cancer therapeutics, 2013, Volume: 12, Issue:8 Topics: Afatinib; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Heterografts; Humans; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Quinazolines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Transcription Factors	2013
NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. Toxicology and applied pharmacology, 2013, Nov-01, Volume: 272, Issue:3 Topics: Autophagy; Carcinoma, Squamous Cell; Cytoprotection; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; HEK293 Cells; Humans; NADPH Oxidase 4; NADPH Oxidases; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured	2013
Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. PloS one, 2013, Volume: 8, Issue:9 Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Niclosamide; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor	2013
Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Molecular cancer therapeutics, 2013, Volume: 12, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Triazoles	2013
EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC. Molecular cancer research : MCR, 2013, Volume: 11, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Cytokines; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inflammation; Lapatinib; NADPH Oxidase 4; NADPH Oxidases; Oligonucleotide Array Sequence Analysis; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Time Factors	2013
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head & neck, 2014, Volume: 36, Issue:11 Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Mice; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sensitivity and Specificity; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transfection	2014
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. Future oncology (London, England), 2014, Volume: 10, Issue:1 Topics: Afatinib; Animals; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Oncogene Proteins v-erbB; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays	2014
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer biology & therapy, 2014, Mar-01, Volume: 15, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Furans; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Quinazolines; ras Proteins; Signal Transduction	2014
Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Pyrazoles; Quinazolines; Sulfonamides	2014
Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer. Antioxidants & redox signaling, 2014, Jul-10, Volume: 21, Issue:2 Topics: Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Phenotype; Phosphorylation; Quinazolines; Radiation Tolerance; Radiation, Ionizing; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured	2014
Nanoimmunoassay to Detect Responses in Head and Neck Cancer: Feasibility in a Mouse Model. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2014, Volume: 151, Issue:1 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Feasibility Studies; Gefitinib; Head and Neck Neoplasms; Heterografts; Immunoassay; In Vitro Techniques; Mice; Nanotechnology; Quinazolines	2014
In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth fact Head & neck, 2015, Volume: 37, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; In Vitro Techniques; Membrane Proteins; Polymerase Chain Reaction; Predictive Value of Tests; Proto-Oncogene Proteins; Quinazolines; Sensitivity and Specificity; Signal Transduction; Vascular Endothelial Growth Factor A	2015
Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation. International journal of biological sciences, 2014, Volume: 10, Issue:7 Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Amyloid Precursor Protein Secretases; Antibodies; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Membrane Proteins; Phosphorylation; Quinazolines; Signal Transduction	2014
Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Molecular cancer therapeutics, 2014, Volume: 13, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Monensin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2014
Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins. Cancer letters, 2014, Nov-28, Volume: 354, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Dual-Specificity Phosphatases; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Male; MAP Kinase Signaling System; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Organophosphates; Panitumumab; Phosphorylation; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2014
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Targeted oncology, 2015, Volume: 10, Issue:4 Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays	2015
MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells. Cancer research, 2015, Apr-15, Volume: 75, Issue:8 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Knockout; Mice, Nude; Myeloid Differentiation Factor 88; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Cells, Cultured	2015
ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. Oncotarget, 2015, Apr-20, Volume: 6, Issue:11 Topics: Anoctamin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Chloride Channels; ErbB Receptors; Fusion Regulatory Protein 1, Heavy Chain; Gefitinib; Head and Neck Neoplasms; HEK293 Cells; Humans; Multiprotein Complexes; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2015
EGFR inhibition for recurrent or metastatic HNSCC. The Lancet. Oncology, 2015, Volume: 16, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Quinazolines	2015
Head and neck cancer: second-line afatinib shows promise. Nature reviews. Clinical oncology, 2015, Volume: 12, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Quinazolines	2015
miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma. Molecular cancer therapeutics, 2015, Volume: 14, Issue:10 Topics: Afatinib; Animals; Antineoplastic Agents; Base Sequence; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; ErbB Receptors; Gene Expression; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Lapatinib; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Proto-Oncogene Proteins c-ets; Quinazolines; RNA Interference; Signal Transduction; Transcription Factors; Tumor Burden	2015
Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin. Molecular medicine reports, 2016, Volume: 13, Issue:3 Topics: Afatinib; Cell Line, Tumor; Cisplatin; DNA Mutational Analysis; ErbB Receptors; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Protein Domains; Quinazolines; Treatment Outcome	2016
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 08-01, Volume: 22, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Female; Gefitinib; Gene Amplification; Gene Expression; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Squamous Cell Carcinoma of Head and Neck	2016
Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer, 2016, 08-01, Volume: 122, Issue:15 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2016
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC. Molecular cancer therapeutics, 2016, Volume: 15, Issue:8 Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Female; Head and Neck Neoplasms; HEK293 Cells; Humans; Mice; Multigene Family; Mutation; NIH 3T3 Cells; Phosphorylation; Quinazolines; Receptor, ErbB-4; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays	2016
ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Cancer letters, 2016, 10-10, Volume: 381, Issue:1 Topics: Amino Acid Transport System ASC; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dichloroacetic Acid; Down-Regulation; Endocytosis; ErbB Receptors; Gefitinib; Glutamine; Glutathione; Head and Neck Neoplasms; Humans; Minor Histocompatibility Antigens; Oxidative Stress; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Reactive Oxygen Species; RNA Interference; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Transfection	2016
Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma. International journal of molecular sciences, 2017, Jan-26, Volume: 18, Issue:2 Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Head and Neck Neoplasms; Humans; Mutant Proteins; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Quinazolines; Rotenone; Squamous Cell Carcinoma of Head and Neck; Time Factors; Tyrphostins	2017
Gefitinib enhances radiotherapeutic effects of Nuclear medicine and biology, 2017, Volume: 48 Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Protein Transport; Quinazolines; Radiation Tolerance; Radiochemistry; Tissue Distribution	2017
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Protein-Tyrosine Kinases; Quinazolines; Transplantation, Heterologous	2008
Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. British journal of cancer, 2008, Jul-08, Volume: 99, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Quinazolines; Radiotherapy; Xenograft Model Antitumor Assays	2008
Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncology reports, 2008, Volume: 20, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured	2008
Promising newer molecular-targeted therapies in head and neck cancer. Drugs, 2008, Volume: 68, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Models, Biological; Niacinamide; Panitumumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib	2008
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-01, Volume: 14, Issue:21 Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; EGF Family of Proteins; Gefitinib; Genes, erbB-1; Glycoproteins; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2008
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-15, Volume: 15, Issue:2 Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; delta-Crystallins; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Homeodomain Proteins; Humans; Mesoderm; Phenotype; Protein Kinase Inhibitors; Quinazolines; Transcription Factors; Zinc Finger E-box-Binding Homeobox 1	2009
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Mar-01, Volume: 15, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation Dosage; Tumor Cells, Cultured	2009
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. The Journal of pathology, 2009, Volume: 218, Issue:1 Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Genes, erbB-2; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Linear Models; Polymorphism, Genetic; Proto-Oncogene Proteins c-met; Quinazolines	2009
Targeting the future in head and neck cancer. The Lancet. Oncology, 2009, Volume: 10, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Quinazolines; Vascular Endothelial Growth Factor A	2009
A case report of thyroid cancer showing a remarkable effect of gefitinib. Auris, nasus, larynx, 2009, Volume: 36, Issue:5 Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Papillary; Female; Gefitinib; Head and Neck Neoplasms; Humans; Incidental Findings; Lung Neoplasms; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography	2009
Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-01, Volume: 15, Issue:7 Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; NF-kappa B; Phosphorylation; Protein Array Analysis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction	2009
PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene, 2009, Jun-18, Volume: 28, Issue:24 Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HCT116 Cells; Head and Neck Neoplasms; Humans; Membrane Proteins; Mice; Mice, Nude; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Protein p73; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2009
Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells. Nanotechnology, 2009, Jun-03, Volume: 20, Issue:22 Topics: Antineoplastic Agents; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lung Neoplasms; Lysosomes; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quantum Dots; Quinazolines; Signal Transduction	2009
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Catechin; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Transcription Factor RelA; Tumor Suppressor Protein p53	2009
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines	2009
Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma. Cancer science, 2009, Volume: 100, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemokines, CXC; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Mutation; Quinazolines; RNA, Messenger	2009
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis, 2009, Volume: 30, Issue:11 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Cisplatin; Commiphora; Drug Synergism; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Neoplasm Transplantation; Phytotherapy; Plant Preparations; Pregnenediones; Quinazolines; STAT3 Transcription Factor	2009
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2010, Volume: 19, Issue:2 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2010
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-15, Volume: 16, Issue:4 Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Mice; Mice, Nude; Mice, SCID; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays	2010
Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib. Oral oncology, 2010, Volume: 46, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Mice; Mice, Nude; Quinazolines; Transplantation, Heterologous	2010
Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncology reports, 2010, Volume: 23, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Lapatinib; Mice; Paclitaxel; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays	2010
Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer research, 2010, Apr-01, Volume: 70, Issue:7 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Phosphorylation; Proto-Oncogene Proteins c-cbl; Quinazolines; Ubiquitin	2010
Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib. The British journal of dermatology, 2010, Volume: 163, Issue:3 Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Keratoacanthoma; Protein Kinase Inhibitors; Quinazolines; Scalp; Skin Neoplasms; Treatment Outcome	2010
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, May-01, Volume: 16, Issue:9 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; Drug Synergism; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lignans; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2010
Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clinical and translational science, 2009, Volume: 2, Issue:3 Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Gefitinib; Gene Dosage; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Quinazolines; RNA, Messenger	2009
Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nature medicine, 2010, Volume: 16, Issue:6 Topics: Animals; Cell Line, Tumor; Dependovirus; ErbB Receptors; Female; Gefitinib; Gene Expression; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Isoantigens; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Receptors, Virus; Transduction, Genetic; Tyrphostins	2010
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head & neck, 2011, Volume: 33, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Disease Models, Animal; ErbB Receptors; Flow Cytometry; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Random Allocation; Sensitivity and Specificity; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2011
Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Sep-01, Volume: 16, Issue:17 Topics: Aged; Animals; Blotting, Western; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays	2010
EGF-dependent induction of BCL-xL and p21CIP1/WAF1 is highly variable in HNSCC cells--implications for EGFR-targeted therapies. Anticancer research, 2010, Volume: 30, Issue:11 Topics: bcl-X Protein; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Head and Neck Neoplasms; Humans; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tyrphostins	2010
EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines. Anticancer research, 2011, Volume: 31, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cetuximab; Codon; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Head and Neck Neoplasms; Humans; Polymorphism, Genetic; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tyrphostins	2011
Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Apr-01, Volume: 29, Issue:10 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiotherapy, Adjuvant; Treatment Outcome	2011
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Burden; Xenograft Model Antitumor Assays	2011
Studies on the inhibition of feline EGFR in squamous cell carcinoma: enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors. Cancer biology & therapy, 2011, Jun-01, Volume: 11, Issue:11 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cats; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Conserved Sequence; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Radiation Tolerance; RNA Interference; Signal Transduction	2011
Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. Cancer research, 2011, Jun-01, Volume: 71, Issue:11 Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Growth Processes; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction; Transfection; Xenograft Model Antitumor Assays	2011
The use of optical technology to monitor the antiangiogenic effects of gefitinib treatment for advanced head and neck squamous cell carcinoma: a brief report. Lasers in medical science, 2012, Volume: 27, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Squamous Cell; Endoscopy; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Optics and Photonics; Quinazolines	2012
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13 Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor alpha; Wound Healing; Xenograft Model Antitumor Assays	2011
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. Journal of cellular physiology, 2011, Volume: 226, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger; Ubiquitination; Vorinostat	2011
Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011, Volume: 99, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Logistic Models; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Statistics, Nonparametric; Tumor Microenvironment	2011
Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways. BMC cancer, 2011, Sep-06, Volume: 11 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Radiation; Epidermal Growth Factor; ErbB Receptors; Flavonoids; Gamma Rays; Head and Neck Neoplasms; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Quinazolines; Signal Transduction; Sirolimus; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Tyrphostins	2011
Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Molecular cancer, 2011, Sep-22, Volume: 10 Topics: Cadherins; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Protein Stability; Quinazolines; RNA Interference; RNA Stability; RNA, Messenger; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured	2011
Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors. Cellular signalling, 2012, Volume: 24, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Dimerization; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Immunoprecipitation; Lapatinib; Plasmids; Protein Conformation; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection	2012
Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. Head & neck, 2012, Volume: 34, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Enteral Nutrition; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Hospitalization; Humans; Male; Middle Aged; Neutropenia; Quinazolines; Radiotherapy Dosage; Registries; Retrospective Studies	2012
Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. Head & neck, 2012, Volume: 34, Issue:9 Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Head and Neck Neoplasms; Humans; Immunoprecipitation; In Vitro Techniques; Mice; Molecular Targeted Therapy; Piperidines; Quinazolines; Signal Transduction; Tumor Cells, Cultured	2012
Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway. British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Phenotype; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Transcription Factors	2012
Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition. Veterinary journal (London, England : 1997), 2012, Volume: 193, Issue:1 Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycoproteins; Head and Neck Neoplasms; Humans; Neoplastic Stem Cells; Peptides; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2012
EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PloS one, 2012, Volume: 7, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplasm Invasiveness; Neoplastic Stem Cells; Quinazolines; Signal Transduction	2012
Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell cycle (Georgetown, Tex.), 2012, Apr-15, Volume: 11, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering	2012
Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality. Head & neck, 2013, Volume: 35, Issue:1 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 1; Podophyllotoxin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2013
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine. Acta dermato-venereologica, 2012, Volume: 92, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Liver Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Scalp; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2012
EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012, Volume: 103, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Membrane Potentials; Patch-Clamp Techniques; Phlorhizin; Protein-Tyrosine Kinases; Quinazolines; Radiation Dosage; Sodium-Glucose Transport Proteins; Tumor Cells, Cultured	2012
Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2012, Volume: 147, Issue:4 Topics: beta Catenin; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Chi-Square Distribution; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Phenotype; Quinazolines; Snail Family Transcription Factors; Transcription Factors; Wound Healing	2012
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer biology & therapy, 2012, Volume: 13, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays	2012
Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma. Head & neck, 2013, Volume: 35, Issue:6 Topics: Basic Helix-Loop-Helix Transcription Factors; Biomarkers; Carcinoma, Squamous Cell; Carrier Proteins; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Glucuronosyltransferase; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction	2013
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-15, Volume: 18, Issue:18 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Xenograft Model Antitumor Assays	2012
Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma. Anticancer research, 2012, Volume: 32, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Lapatinib; Quinazolines	2012
Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma. International journal of cancer, 2013, Mar-01, Volume: 132, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; GRB2 Adaptor Protein; Head and Neck Neoplasms; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2013
Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. Head & neck, 2013, Volume: 35, Issue:9 Topics: Adolescent; Adult; Carcinoma, Squamous Cell; Cell Culture Techniques; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Young Adult	2013
Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer. Cancer biology & therapy, 2012, Volume: 13, Issue:14 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dihematoporphyrin Ether; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Photochemotherapy; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor	2012
A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PloS one, 2012, Volume: 7, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Lineage; Cell Proliferation; Cell Shape; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Flow Cytometry; Gamma Rays; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Organ Specificity; Quinazolines	2012
Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7. PloS one, 2012, Volume: 7, Issue:10 Topics: 3' Untranslated Regions; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Signal Transduction	2012
Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PloS one, 2012, Volume: 7, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Auranofin; Buthionine Sulfoximine; Carcinoma, Squamous Cell; Catalase; Cell Line, Tumor; Cell Survival; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Necrosis; Oxidation-Reduction; Oxidative Stress; Peroxiredoxins; Quinazolines; RNA, Small Interfering; Thioredoxin-Disulfide Reductase; Thioredoxins; Xenograft Model Antitumor Assays	2012
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer research, 2013, Jan-15, Volume: 73, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays	2013
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Molecular oncology, 2013, Volume: 7, Issue:3 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Mutation; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2013
c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jan-15, Volume: 19, Issue:2 Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Gene Expression; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Transcriptional Activation	2013
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:11 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Quinazolines; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays	2012
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC cancer, 2013, Jan-18, Volume: 13 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; DNA, Viral; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Panitumumab; Proportional Hazards Models; Quinazolines; Retrospective Studies	2013
A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and ne Molecular pharmacology, 2013, Volume: 83, Issue:4 Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gene Regulatory Networks; Head and Neck Neoplasms; Humans; Oncogene Proteins v-erbB; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Fibroblast Growth Factor	2013
Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer research, 2002, Aug-01, Volume: 62, Issue:15 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Endothelium, Vascular; ErbB Receptors; Female; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2002
Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer research, 2002, Nov-01, Volume: 62, Issue:21 Topics: Carcinoma, Squamous Cell; Cell Division; Cell Movement; DNA, Neoplasm; Enzyme Inhibitors; ErbB Receptors; GTP-Binding Proteins; Head and Neck Neoplasms; Humans; Lysophospholipids; MAP Kinase Signaling System; Metalloendopeptidases; Phosphorylation; Quinazolines; Receptor, ErbB-2; S Phase; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Tyrphostins	2002
Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. Journal of cellular physiology, 2003, Volume: 195, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Macromolecular Substances; Oligonucleotides, Antisense; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins	2003
Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer research, 2003, Jun-01, Volume: 63, Issue:11 Topics: Antigens, CD; Apoptosis; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cytokine Receptor gp130; DNA-Binding Proteins; Enzyme Inhibitors; ErbB Receptors; Head and Neck Neoplasms; Humans; Interleukin-6; Membrane Glycoproteins; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Trans-Activators; Tumor Cells, Cultured; Tyrphostins	2003
Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. British journal of cancer, 2003, Aug-04, Volume: 89, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cisplatin; DNA Repair; Drug Interactions; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured	2003
Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor. American journal of clinical oncology, 2003, Volume: 26, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Radiation Tolerance	2003
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-15, Volume: 9, Issue:13 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Primers; Floxuridine; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Models, Chemical; Polymerase Chain Reaction; Pyrimidines; Quinazolines; RNA; RNA, Messenger; Time Factors; Transcription, Genetic	2003
Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proceedings of the National Academy of Sciences of the United States of America, 2003, Dec-23, Volume: 100, Issue:26 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Glioma; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrphostins	2003
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2 Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; CSK Tyrosine-Protein Kinase; Cytoskeleton; Disease Progression; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; p21-Activated Kinases; Phenotype; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Transfection; Vinculin	2004
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer research, 2004, Aug-01, Volume: 64, Issue:15 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured	2004
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17 Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins	2004
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22 Topics: Antineoplastic Agents; Blotting, Southern; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; G1 Phase; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Vectors; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Prognosis; Protein Kinase Inhibitors; Quinazolines; S Phase; Time Factors	2004
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer research, 2004, Dec-15, Volume: 64, Issue:24 Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin	2004
[Successes in late solid tumors. New therapy offer]. MMW Fortschritte der Medizin, 2004, Nov-18, Volume: 146, Issue:47 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Leucovorin; Organoplatinum Compounds; Palliative Care; Quinazolines; Salvage Therapy; Time Factors	2004
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Molecular & cellular proteomics : MCP, 2005, Volume: 4, Issue:4 Topics: Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Chromatography, Affinity; Chromatography, Liquid; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoblotting; Isotopes; Mass Spectrometry; Models, Biological; Peptide Mapping; Phosphorylation; Phosphotyrosine; Proteins; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; src-Family Kinases	2005
The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells. Cell proliferation, 2005, Volume: 38, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Suppressor Protein p53	2005
Profiling EGFR activity in head and neck squamous cell carcinoma by using a novel layered membrane Western blot technology. Oral oncology, 2005, Volume: 41, Issue:5 Topics: Blotting, Western; Carcinoma, Squamous Cell; Cell Communication; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Quinazolines; Signal Transduction; Tyrphostins	2005
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides	2005
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; DNA-Binding Proteins; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Immunoblotting; Immunoenzyme Techniques; Membrane Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostaglandins E; Pyrazoles; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Sulfonamides; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2005
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Nov-15, Volume: 11, Issue:22 Topics: Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2005
Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer research, 2006, Jan-15, Volume: 66, Issue:2 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Deoxycytidine; Drug Administration Schedule; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Quinazolines; Tumor Cells, Cultured	2006
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-15, Volume: 12, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; In Vitro Techniques; Interferon-alpha; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2006
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer research, 2006, Mar-15, Volume: 66, Issue:6 Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Sp1 Transcription Factor; Vascular Endothelial Growth Factor A	2006
EGFR regulates the side population in head and neck squamous cell carcinoma. The Laryngoscope, 2006, Volume: 116, Issue:3 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Vitro Techniques; Neoplasm Proteins; Quinazolines	2006
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-01, Volume: 12, Issue:13 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Male; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA; Signal Transduction; Structure-Activity Relationship; Time Factors	2006
Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS letters, 2006, Sep-04, Volume: 580, Issue:20 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Cisplatin; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Head and Neck Neoplasms; Humans; Phosphorylation; Quinazolines; Tyrosine; Tyrphostins	2006
Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. British journal of cancer, 2006, Sep-18, Volume: 95, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Organophosphorus Compounds; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays	2006
Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:3 Topics: Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; In Vitro Techniques; Inhibitory Concentration 50; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Vinblastine; Vinorelbine	2007
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncology reports, 2007, Volume: 17, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Quinazolines	2007
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Quinazolines; Skin	2007
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. British journal of cancer, 2007, Mar-26, Volume: 96, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Growth Inhibitors; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2007
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2 Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2008
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Molecular cancer therapeutics, 2007, Volume: 6, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Invasiveness; Quinazolines; Receptors, Bombesin; Signal Transduction; Tumor Stem Cell Assay	2007
Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-15, Volume: 13, Issue:8 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Mice; Mice, Nude; Quinazolines; Rats; Transplantation, Heterologous	2007
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-15, Volume: 13, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microtubules; Mitosis; Pyrazoles; Quinazolines; Sulfonamides; Taxoids	2007
Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-01, Volume: 25, Issue:16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Head and Neck Neoplasms; Humans; Polymerase Chain Reaction; Quality of Life; Quinazolines	2007
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Molecular cancer therapeutics, 2007, Volume: 6, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gefitinib; Head and Neck Neoplasms; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Quinazolines	2007
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. Anti-cancer drugs, 2007, Volume: 18, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Leucovorin; Quinazolines; Thiophenes	2007
Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. British journal of cancer, 2007, Jul-02, Volume: 97, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous; Xenograft Model Antitumor Assays	2007
[Role of targeted therapy in the treatment of squamous cell head and neck cancer]. Magyar onkologia, 2007, Volume: 51, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant	2007
Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer research, 2007, Oct-01, Volume: 67, Issue:19 Topics: Anoikis; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Growth Processes; Chromosomes, Human, Pair 11; Cortactin; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction	2007
Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2007, Volume: 85, Issue:1 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Receptor, ErbB-3; Vinblastine; Vinorelbine	2007
Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncology reports, 2008, Volume: 19, Issue:1 Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Molecular Sequence Data; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2008
Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head & neck, 2008, Volume: 30, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Dideoxynucleosides; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines	2008
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7 Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Squamous Cell; Ovarian Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Quinazolines	2008
Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Molecular pharmacology, 2008, Volume: 73, Issue:6 Topics: Animals; Antineoplastic Agents; bcl-X Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays	2008
Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. Anti-cancer drugs, 2008, Volume: 19, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Quinazolines; Taxoids	2008
Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. International journal of molecular medicine, 2008, Volume: 21, Issue:6 Topics: Acid Anhydride Hydrolases; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; DNA-Binding Proteins; ErbB Receptors; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Immunoprecipitation; Inhibitory Concentration 50; Membrane Proteins; Mutation; Neoplasm Proteins; Nuclear Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2008
Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. Molecular pharmacology, 1995, Volume: 48, Issue:4 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Head and Neck Neoplasms; Humans; Kinetics; Methotrexate; Ornithine; Pterins; Pteroylpolyglutamic Acids; Quinazolines; Tetrahydrofolate Dehydrogenase; Tritium; Tumor Cells, Cultured	1995
Clinical trials referral resource. Clinical trials with tomudex. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:7 Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Folic Acid Antagonists; Head and Neck Neoplasms; Humans; Leukemia; Male; Prostatic Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase	1996
EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. International journal of oncology, 1998, Volume: 13, Issue:2 Topics: Antibodies, Monoclonal; Apoptosis; Carcinoma, Squamous Cell; Cell Differentiation; Cell Division; Enzyme Inhibitors; ErbB Receptors; Head and Neck Neoplasms; Humans; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Tyrosine	1998
Interaction of tomudex with radiation in vitro and in vivo. International journal of oncology, 1998, Volume: 13, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Survival; Combined Modality Therapy; Drug Interactions; Enzyme Inhibitors; Fluorouracil; Head and Neck Neoplasms; HT29 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms; Quinazolines; Radiation Tolerance; Thiophenes; Thymidylate Synthase; Transplantation, Heterologous; Tumor Cells, Cultured	1998
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:7 Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes; Thymidine; Transplantation, Heterologous; Tumor Cells, Cultured	1999
Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells. Oncology research, 1999, Volume: 11, Issue:2 Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cytochrome c Group; Dimerization; Dose-Response Relationship, Drug; Enzyme Activation; Head and Neck Neoplasms; Humans; Mitochondria; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Thiophenes; Thymidylate Synthase; Transfection; Tumor Cells, Cultured	1999
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 291, Issue:2 Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Phosphotyrosine; Polypharmacy; Quinazolines; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine	1999
Characterization of the effect of AG337, a novel lipophilic thymidylate synthase inhibitor, on human head and neck and human leukemia cell lines. International journal of oncology, 1999, Volume: 15, Issue:6 Topics: Cell Cycle; Cell Division; Culture Media; Drug Resistance; Enzyme Inhibitors; Fetal Blood; Head and Neck Neoplasms; Humans; Hypoxanthine; Inhibitory Concentration 50; Leucovorin; Leukemia; Methotrexate; Quinazolines; Thymidine; Thymidine Phosphorylase; Thymidylate Synthase; Tumor Cells, Cultured	1999
Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:2 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured	2000
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer research, 2001, Sep-01, Volume: 61, Issue:17 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Keratinocytes; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Quinazolines; Signal Transduction; Skin; Transforming Growth Factor beta	2001
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. British journal of cancer, 2002, Mar-04, Volume: 86, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Gefitinib; Genes, p53; Head and Neck Neoplasms; Humans; Quinazolines; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured	2002
Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). British journal of cancer, 2002, May-06, Volume: 86, Issue:9 Topics: Antineoplastic Agents; Blotting, Western; Colonic Neoplasms; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2002
Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer research, 1989, Oct-01, Volume: 49, Issue:19 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Resistance; Head and Neck Neoplasms; Humans; Methotrexate; Peptide Synthases; Peptides; Polyglutamic Acid; Quinazolines; Thymidylate Synthase; Time Factors; Trimetrexate; Tumor Cells, Cultured	1989
Trimetrexate as a single agent in patients with advanced head and neck cancer. Seminars in oncology, 1988, Volume: 15, Issue:2 Suppl 2 Topics: Adult; Aged; Antineoplastic Agents; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines; Trimetrexate	1988